Unichem Alfuzosin Hydrochloride extended-release tablet

Unichem's Alfuzosin Hydrochloride Extended-Release Tablets are a generic pharmaceutical product used primarily for the treatment of benign prostatic hyperplasia (BPH). The product is manufactured in India, with the finished dosage forms typically produced at Unichem's USFDA-approved facility in Goa. The active pharmaceutical ingredient (API) is also produced in-house at their plant in Pithampur, India.

The brand originates from India, where Unichem Laboratories was established in 1944. Historically an independent Indian company, its ownership landscape changed significantly in 2023 when Ipca Laboratories Limited, another major Indian pharmaceutical entity, acquired a controlling stake (approximately 52.67%) of the company. Today, Unichem operates as a subsidiary under the umbrella of Ipca Laboratories, maintaining its global presence through subsidiaries like Unichem Pharmaceuticals (USA), Inc., which handles distribution in the United States.